A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1;
* Subjects who are chemotherapy naive and have Stage IIIB-IV non-squamous NSCLC;
* Gene diagnostic tests must show that subjects are with wild type of EGFR, ALK and ROS1;
* Known PD-L1 status as determined by immunohistochemistry assay performed on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening;
* No prior systemic treatment;
* Adequate hematologic and end organ function;
* Female participants of childbearing potential must have a negative serum pregnancy test within -7 days of randomization and must be willing to use very efficient barrier methods of contraception or a barrier method plus a hormonal method starting with the screening visit through 6 months after the last dose Male participants with a female partner(s) of child-bearing potential must be willing to use very efficient barrier methods of contraception from screening through 6 months after the last dose.

Exclusion Criteria:

* Significant cardiovascular disease;
* Prior treatment with immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies;
* History of autoimmune disease;
* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome;
* Severe infection within 4 weeks prior to randomization;
* Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live attenuated vaccine will be required during the study;
* Major surgical procedure within 4 weeks prior to randomization;
* History of hemoptysis within 12 weeks prior to randomization;
* Inadequately controlled hypertension;
* Evidence of bleeding diathesis or coagulopathy;
* Prior allogeneic bone marrow transplantation or solid organ transplant;
* Positive test for HIV, and patients with active hepatitis B or hepatitis C.